New anti-osteoporotic agents have been developed, potentially enriching the therapeutic
armamentarium. Currently available osteoanabolic therapies are the parathyroid hormone …

There has been substantial progress in the management of patients with osteoporosis and
the prevention of osteoporotic fractures. Currently available strong anti-resorptive agents are …

Current osteoporosis medications reduce fractures significantly but have rare and serious
adverse effects (osteonecrosis of the jaw, atypical femoral fractures) that may limit their …

Although several effective therapies are available for the treatment of osteoporosis in
postmenopausal women and older men, there remains a need for the development of even …

Introduction: Pharmacological options to address the imbalance between bone resorption
and accrual in osteoporosis include anti-resorptive and osteoanabolic agents. Unique …

Bone forming approaches to treat patients with severe osteoporosis are effective, but
treatment options are limited and there is an unmet clinical need for additional drugs. This …

In the absence of an intervening antiresorptive agent, cyclic administration of teriparatide
does not increase bone mineral density (BMD) more than standard daily therapy. Because …

Since the identification of osteoporosis as a major health issue in aging populations and the
subsequent development of the first treatment modalities for its management, considerable …

The treatment of osteoporosis is generally either by inhibition of bone resorption with
antiresorptive agents or by stimulation of bone formation with anabolic agents. Currently …

Osteoporosis is characterized by low bone mass and qualitative structural abnormalities of
bone tissue, leading to increased bone fragility that results in fractures. Pharmacological …